Cellomics
From Wikipedia, the free encyclopedia
| Cellomics | |
|---|---|
 |
|
| Type | Private company |
| Founded | 1996 |
| Location | Pittsburgh, PA, USA |
| Key people | Dan Calvo President and CEO |
| D. Lansing Taylor Founder |
|
| Industry | Biotechnology |
| Products | complete High-content screening platform |
| Revenue | (not available) |
| Website | http://www.cellomics.com/ |
Cellomics is a privately held company which is the self-described inventor of high-content screening (HCS). Cellomics the company takes its name from cellomics the term, which the company describes as meaning "the study of cells" or "the knowledge of cellular phenotype and function". Cellomics provides to customers analysis platforms designed to facilitate the study of cells in culture, particularly their responses to potentially therapeutic drug-like molecules.
[edit] Products
One type of product provided by Cellomics allows the monitoring of cell shape or the localization of intracellular labels in response to stimuli. Reported uses of this product type include assessment of neurite outgrowth from neurons treated with drug compounds and assay for nuclear translocation of labeled proteins. Cellomics also provides data-mining software for extracting information from high-content screening data.
[edit] Notes
- ^ Cellomics corporate facts. Retrieved 4 July, 2005.
- ^ Cellomics definitions page. Retrieved 4 July, 2005.
- ^ Aldridge, Susan (March 15, 2005). "Screening technology challenges". Genetic Engineering News, 25(6):16.
- Cellomics Board of Directors. Retrieved 4 July, 2005.
 |
This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it. |
